Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Portico NG-godkjenningsstudie

13. november 2026 oppdatert av: Abbott Medical Devices

Evaluering av Portico™ NG (neste generasjon) transkateter aortaklaff hos pasienter med høy og ekstrem risiko med symptomatisk alvorlig aortastenose

The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.

Studieoversikt

Detaljert beskrivelse

The Portico NG Approval study will be conducted as a prospective, multi-center, international, single-arm investigational study.

Up to 399 (includes up to 20 roll-ins) high or extreme risk patients with symptomatic, severe native aortic stenosis who are determined by an independent subject selection committee to meet eligibility criteria for Navitor Transcatheter Aortic Heart Valve implantation will undergo Navitor Valve implantation via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR (transcatheter aortic valve replacement) procedure.

Subjects participating in the clinical study will be followed for a total of 12 months with data collected at screening, baseline, procedure, prior to hospital discharge, and follow-up at 30 days, 12 months and annually through 10 years.

This study will also include a product size extension, Navitor Titan™ valve, which includes up to 90 subjects (Titan cohort) who will undergo an implant attempt with the Navitor Titan valve. Subjects enrolled in the Titan cohort will undergo the same screening, baseline, procedure and follow-up assessments as the Portico NG cohort.

Studietype

Intervensjonell

Registrering (Faktiske)

333

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • St. Andrew's Hospital
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • The Alfred Hospital
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Fiona Stanley Hospital
      • Copenhagen, Danmark, 2100
        • Rigshospitalet
    • California
      • Los Angeles, California, Forente stater, 90048
        • Cedars-Sinai Medical Center
      • Thousand Oaks, California, Forente stater, 91360
        • Los Robles Regional Medical Center
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20010
        • MedStar Washington Hospital Center
    • Illinois
      • Oak Lawn, Illinois, Forente stater, 60453
        • Advocate Christ Medical Center
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46240
        • Ascension St. Vincent
    • Kansas
      • Wichita, Kansas, Forente stater, 67214
        • Ascension Via Christi Hospitals Wichita
    • Michigan
      • Lansing, Michigan, Forente stater, 48912
        • Sparrow Clinical Research Institute
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55407
        • Minneapolis Heart Institute Foundation
    • New Jersey
      • Morristown, New Jersey, Forente stater, 07962
        • Morristown Medical Center
    • New York
      • Albany, New York, Forente stater, 12208
        • Albany Medical Center
      • New York, New York, Forente stater, 10032
        • Columbia Univ. Medical Center/NewYork-Presbyterian Hospital
      • New York, New York, Forente stater, 10467
        • Montefiore Medical Center - Moses Campus
    • North Carolina
      • Asheville, North Carolina, Forente stater, 28801
        • Mission Hospital
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • University Hospitals Cleveland Medical Center
    • Oregon
      • Portland, Oregon, Forente stater, 97225
        • Providence St. Vincent Medical Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • UPMC
    • Tennessee
      • Memphis, Tennessee, Forente stater, 38120
        • Baptist Memorial Hospital
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Houston Methodist
      • Plano, Texas, Forente stater, 75093
        • Baylor Scott & White - The Heart Hospital Plano
    • Utah
      • St. George, Utah, Forente stater, 84790
        • Intermountain St. George Regional Hospital
    • Virginia
      • Norfolk, Virginia, Forente stater, 23507
        • Sentara Norfolk General Hospital
    • Lombard
      • San Donato Milanese, Lombard, Italia, 20097
        • Policlinico San Donato
    • Northern Ireland
      • Belfast, Northern Ireland, Storbritannia, BT12 6BA
        • Royal Victoria Hospital
    • SWANSEA
      • Morriston, SWANSEA, Storbritannia, SA6 6NL
        • Morriston Hospital - ABM University Health Board

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  1. Subjects must have a Society of Thoracic Surgeons (STS) score of ≥7% OR documented heart team agreement of high or extreme risk for surgical aortic valve replacement due to frailty or co-morbidities not captured by the STS score.
  2. Subject has symptomatic aortic stenosis as demonstrated by NYHA (New York Heart Association) Functional Classification of II, III, or IV.
  3. Subject has senile degenerative aortic valve stenosis with echo-derived criteria, defined as: aortic valve area (AVA) of ≤ 1.0 cm2 (or indexed EOA (effective orifice area) ≤ 0.6 cm2/m2) AND mean gradient ≥40 mmHg or peak jet velocity ≥ 4.0 m/s or doppler velocity index (DVI) ≤0.25. (Qualifying AVA baseline measurement must be within 90 days prior to informed consent).
  4. Aortic annulus diameter of 19-30mm and ascending aorta diameter for the specified valve size listed in the IFU (Instructions For Use), as measured by CT (Computed Tomography)

Key Exclusion Criteria:

  1. Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as evidenced on 12 Lead ECG) within 30 days prior to index procedure.
  2. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to index procedure.
  3. Blood dyscrasias as defined: leukopenia (WBC<3000 mm3), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count <50,000 cells/mm³). History of bleeding diathesis or coagulopathy
  4. Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that would preclude anticoagulation
  5. Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA).
  6. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+).
  7. Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic ring, severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the left ventricular outflow tract (LVOT), severe (greater than or equal to 3+) mitral insufficiency, or severe mitral stenosis with pulmonary compromise.
  8. Minimum access vessel diameter of <5.0mm for small FlexNav™ Delivery System and <5.5 mm for large FlexNav™ Delivery System

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Portico™ NG (Navitor) valve, FlexNav™ Delivery System

Portico ™ NG (Navitor) valve implantation with the new generation Portico NG (Navitor) valve (23mm, 25mm, 27mm and 29mm sizes), and the second-generation FlexNav Delivery system (small and large), Portico™ NG (Navitor) Loading System(s) (small and large).

Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

Eksperimentell: Navitor Titan Valve

Navitor Titan Valve (35mm) implantation with the large FlexNav Delivery system and Navitor Loading System - LG+.

Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Primary Safety Endpoint is All-cause Mortality
Tidsramme: at 30 days

All-cause mortality is defined as the total number of deaths in each cohort at 30 days.

at 30 days
Primary Effectiveness Endpoint is Moderate or Greater Paravalvular Leak
Tidsramme: at 30 days

Number of participants with moderate or greater paravalvular leak at 30 days.

at 30 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Non-hierarchical Composite of All-cause Mortality, Disabling Stroke, Life Threatening Bleeding, Acute Kidney Injury (Stage 3), or Major Vascular Complications
Tidsramme: at 30 days

The secondary endpoint is defined as a non-hierarchical composite of all-cause mortality, disabling stroke, life threatening bleeding, acute kidney injury (stage 3), or major vascular complications at 30 days.

at 30 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. september 2019

Primær fullføring (Faktiske)

12. januar 2023

Studiet fullført (Antatt)

1. januar 2033

Datoer for studieregistrering

Først innsendt

4. juli 2019

Først innsendt som oppfylte QC-kriteriene

4. juli 2019

Først lagt ut (Faktiske)

8. juli 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere